Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Ifosfamide and Doxorubicin Combination Chemotherapy for Recurrent Nasopharyngeal Carcinoma Patients

  • Dede, Didem Sener (Department of Medical Oncology, Hacettepe University Faculty of Medicine) ;
  • Aksoy, Sercan (Department of Medical Oncology, Hacettepe University Faculty of Medicine) ;
  • Cengiz, Mustafa (Department of Radiation Oncology, Hacettepe University Faculty of Medicine) ;
  • Gullu, Ibrahim (Department of Medical Oncology, Hacettepe University Faculty of Medicine) ;
  • Altundag, Kadri (Department of Medical Oncology, Hacettepe University Faculty of Medicine)
  • Published : 2012.05.30
Download PDF
⟨ Previous Next ⟩

Abstract

Background: We assessed the efficacy and toxicity of ifosfamide and doxorubicin combination chemotherapy (CT) regimen retrospectively in Turkish patients with recurrent or metastatic nasopharyngeal carcinoma (NPC) previously treated with platinum-based chemotherapy. Methods: A total of thirty patients who had received cisplatin based chemotherapy/chemoradiotherapy as a primary treatment received ifosfamide 2500 $mg/m^2$ days 1-3, mesna 2500 $mg/m^2$ days 1-3, doxorubicin 60 mg/m2 day 1 (IMA), repeated every 21 days. Eligible patients had ECOG PS< 2, measurable recurrent or metastatic disease, with adequate renal, hepatic and hematologic functions. Results: Median age was 47 (min-max; 17-60). Twenty six (86.7 %) were male. Median cycles of chemotherapy for each patient were 2 (range:1-6). Twenty patients were evaluable for toxicity and response. No patient achieved complete response, with nine partial responses for a response rate of 30.0% in evaluable patients. Stable disease, and disease progression were observed in five (16.7%) and six (20.0%) patients, respectively. Clinical benefit was 46.7%. Median time to progression was 4.0 months. Six patients had neutropenic fever after IMA regimen and there were one treatment-related death due to tumor lysis syndrome in first cycle of the CT. No cardiotoxicity was observed after CT and treatments were generally well tolerated. Conclusion: Ifosfomide and doxorubicin combination is an effective regimen for patients with recurrent and metastatic NPC. For NPC patients demonstrating failure of cisplatin based regimens, this CT combination may be considered as salvage therapy.

Keywords

References

  1. Altundag K, Aksoy S, Gullu I, et al (2004). Salvage ifosfamidedoxorubicin chemotherapy in patients with recurrent nasopharyngeal carcinoma pretreated with Cisplatin-based chemotherapy. Med Oncol, 21, 211-5. https://doi.org/10.1385/MO:21:3:211
  2. Au E, Ang PT (1994). A phase II trial of 5-fluorouracil and cisplatinum in recurrent or metastatic nasopharyngeal carcinoma. Ann Oncol, 5, 87-9. https://doi.org/10.1093/annonc/5.suppl_3.S87
  3. Azli N, Fandi A, Bachouchi M, et al (1995). Final report of a phase II study of chemotherapy with bleomycin, epirubicin, and cisplatin for locally advanced and metastatic/recurrent undifferentiated carcinoma of the nasopharyngeal type. Cancer J Sci Am, 1, 222-9.
  4. Boussen H, Cvitkovic E, Wendling JL, et al (1991). Chemotherapy of metastatic and/or recurrent undifferentiated nasopharyngeal carcinoma with cisplatin, bleomycin, and fluorouracil. J Clin Oncol, 9, 1675-81. https://doi.org/10.1200/JCO.1991.9.9.1675
  5. Chan AT, Grégoire V, Lefebvre JL, et al (2010). Nasopharyngeal cancer: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 21, 187-9. https://doi.org/10.1093/annonc/mdp494
  6. Chan ATC, Ma B, Tung S, et al (2007). Biweekly gemcitabine and oxaliplatin (GEMOX) in first-line metastatic or recurrent nasopharyngeal carcinoma (NPC) an early report. J Clin Oncol Proc Am Soc Clin Oncol, 25, 6071.
  7. Chua DT, Kwong DLW, Sham JS, et al (2000). A phase II study of ifosfamide, 5-fluorouracil and leucovorin in patients with recurrent nasopharyngeal carcinoma previously treated with platinum chemotherapy. Eur J Cancer, 36, 736-41. https://doi.org/10.1016/S0959-8049(00)00008-3
  8. Chua DT, Sham JS, Au GK, et al (2003). A phase II study of capecitabine in patients with recurrent and metastatic nasopharyngeal carcinoma pretreated with platinum-based chemotherapy. Oral Oncol, 39, 361-6. https://doi.org/10.1016/S1368-8375(02)00120-3
  9. Chua DT, Sham JS, Au GK, et al (2005). A phase II study of docetaxel and cisplatin as first-line chemotherapy in patients with metastatic nasopharyngeal carcinoma. Oral Oncol, 41, 589-95. https://doi.org/10.1016/j.oraloncology.2005.01.008
  10. Fong KW, Chua EJ, Chua ET, et al (1996). Patient profile and survival in 270 computer tomography-staged patients with nasopharyngeal cancer treated at the Singapore general hospital. Ann Acad Med Singapore, 25, 341-6.
  11. Foo KF, Tan EH, Leong SS, et al (2002). Gemcitabine in metastatic nasopharyngeal carcinoma of the undifferentiated type. Ann Oncol, 13, 150-6. https://doi.org/10.1093/annonc/mdf002
  12. Guo Y, Glisson BS (2010). Systemic treatment for incurable recurrent and/or metastatic nasopharyngeal carcinoma. In 'Nasopharyngeal cancer multidisciplinary management. Eds Lu JJ, Cooper JS and Lee AWM. Springer -Verlag Berlin Heidelberg, pp 267-75.
  13. Hasbini A, Mahjoubi R, Fandi A, et al (1999). Phase II trial combining mitomycin with 5-fluorouracil, epirubicin, and cisplatin in recurrent and metastatic undifferentiated carcinoma of nasopharyngeal type. Ann Oncol, 10, 421-5. https://doi.org/10.1023/A:1008342828496
  14. Huang HQ, Zhou ZM, Li YH, et al (2002). Preliminary results of ifosfamide and doxorubicin regimen in treatment of patients with recurrent and metastatic nasopharyngeal carcinoma. Ai Zheng, 21, 409-11.
  15. Leong SS, Wee J, Tay MH (2005). Paclitaxel, carboplatin, and gemcitabine in metastatic nasopharyngeal carcinoma: a phase II trial using a triplet combination. Cancer, 103, 569-75. https://doi.org/10.1002/cncr.20804
  16. Ma BB, Hui EP, Chan AT, et al (2008). Systemic approach to improving treatment outcome in nasopharyngeal carcinoma: current and future directions. Cancer Sci, 99, 1311-8. https://doi.org/10.1111/j.1349-7006.2008.00836.x
  17. Ma BB, Tannock IF, Pond GR et al (2002). Chemotherapy with gemcitabine-containing regimens for locally recurrent or metastatic nasopharyngeal carcinoma. Cancer, 95, 2516-23. https://doi.org/10.1002/cncr.10995
  18. McCarthy JS, Tannock IF, Degendorfer P, et al (2002). A phase II trial of docetaxel and cisplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. Oral Oncol, 38, 686-90. https://doi.org/10.1016/S1368-8375(01)00134-8
  19. Ngan RK, Yiu HH, Lau WH, et al (2002). Combination gemcitabine and cisplatin chemotherapy for metastatic or recurrent nasopharyngeal carcinoma: report of a phase II study. Ann Oncol, 13, 1252-8. https://doi.org/10.1093/annonc/mdf200
  20. Onat H, Basaran M, Esassolak, et al (2002). High-dose epirubicin and cisplatin in locally advanced undifferentiated nasopharyngeal carcinoma. Clin Oncol, 14, 449-54. https://doi.org/10.1053/clon.2002.0110
  21. Perez CA, Devineni VR, Marcial-Vega V, et al(1992). Carcinoma of the nasopharynx: factors affecting prognosis. Int J Radiat Oncol Biol Phys, 23, 271-80. https://doi.org/10.1016/0360-3016(92)90741-Y
  22. Razak AR, Siu LL, Liu FF et al (2010). Nasopharyngeal carcinoma: the next challenges. Eur J Cancer, 46, 1967-78. https://doi.org/10.1016/j.ejca.2010.04.004
  23. Siu LL, Czaykowski PM, Tannock IF, et al (1998). Phase I/II study of the CAPABLE regimen for patients with poorly differentiated carcinoma of the nasopharynx. J Clin Oncol, 16, 2514-21. https://doi.org/10.1200/JCO.1998.16.7.2514
  24. Taamma A, Fandi A, Azli N, et al (1999). Phase II trial of chemotherapy with 5-fluorouracil, bleomycin, epirubicin, and cisplatin for patients with locally advanced, metastatic, or recurrent undifferentiated carcinoma of the nasopharyngeal type. Cancer, 86, 1101-8. https://doi.org/10.1002/(SICI)1097-0142(19991001)86:7<1101::AID-CNCR2>3.0.CO;2-R
  25. Wang J, Li J, Hong X, et al (2008). Retrospective case series of gemcitabine plus cisplatin in the treatment of recurrent and metastatic nasopharyngeal carcinoma. Oral Oncol, 44, 464-70. https://doi.org/10.1016/j.oraloncology.2007.06.004
  26. Wei KR, Yu YL, Yang YY, et al (2010). Epidemiological trendsof nasopharyngeal carcinoma in China. Asian Pac J Cancer Prev, 11, 29-32.
  27. Wei K, Xu Y, Liu J, et al (2010). No incidence trends and no change inpathological proportions of nasopharyngeal carcinoma in Zhongshan in 1970-2007. Asian Pac J Cancer Prev, 11,1595-9.
  28. Yeo W, Leung TW, Chan AT, et al (1998). A phase II study combination of paclitaxel and carboplatin in advanced nasopharyngeal carcinoma. Eur J Cancer, 34, 2027-31. https://doi.org/10.1016/S0959-8049(98)00280-9

Cited by

  1. Biomarkers for monitoring chemotherapy-induced cardiotoxicity vol.54, pp.2, 2017, https://doi.org/10.1080/10408363.2016.1261270